Shares of Sun Pharmaceutical Industries experienced significant selling pressure on Friday, May 22, falling 2.47% from ₹1,891.30 to ₹1,844.60. According to latest trading data, the stock fluctuated 3.81% during the session, touching a day low of ₹1,833.10 and a high of ₹1,903.00. The stock has shown mixed performance over the past two weeks, declining 0.18% during this period. Trading volume increased by 2 million shares on Friday, indicating heightened selling interest, though the stock has maintained its position within a wider rising trend in the short term.
India's largest pharmaceutical company reported a consolidated net profit of ₹2,714 crore for the January-March quarter of FY26, registering a 26.2% increase compared with ₹2,150 crore reported during the same quarter last year. As reported by Goodreturns, revenue from operations also posted strong growth, rising 12.8% year-on-year to ₹14,612 crore from ₹12,959 crore in Q4FY25, supported by stable domestic demand and continued performance across key global markets. The company also disclosed exceptional gains worth nearly ₹1,700 crore during FY26, including exceptional items of ₹1,307.5 crore along with an exceptional tax credit of ₹385.4 crore for the financial year ended March 31, 2026.
Sun Pharma's board recommended a final dividend of ₹5 per equity share of face value Re 1 for FY26, translating into a 500% dividend payout. According to Goodreturns, earlier during the financial year, the company had already paid an interim dividend of ₹11 per share. This takes the total dividend payout for FY26 to ₹16 per share, unchanged from the previous financial year. The company's consistent dividend policy demonstrates its commitment to returning value to shareholders despite the strong growth trajectory.
For the full financial year FY26, Sun Pharma reported net profit of ₹11,479.4 crore, reflecting annual growth of 5%. As reported by Goodreturns, revenue from operations increased 11.9% to ₹58,220.1 crore. The company also posted improved operating performance during the year. EBITDA rose 16.1% to ₹17,731.4 crore, while EBITDA margin expanded to 30.3% from 29% in FY25**, indicating better operational efficiency and stronger contribution from high-margin businesses.
The company's domestic formulations business remained one of the strongest contributors to overall growth during the quarter, with revenue increasing 14.8% in Q4FY26. According to Goodreturns, for the full financial year, the India business contributed nearly 33% of the company's consolidated sales after recording 14% annual growth. The US formulations business remained relatively steady during the quarter, with revenue standing at 459 million dollars and contributing around 29% of Sun Pharma's consolidated FY26 sales. However, technical analysis suggests mixed signals with a sell candidate rating and negative evaluation due to recent weakness. The stock is expected to move between ₹1,723.66 and ₹1,998.74 over the next three months, with a 4.55% expected rise despite current technical headwinds.
